Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Inventory (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Inventory for 14 consecutive years, with $11.0 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 15.84% to $11.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.0 million through Dec 2025, up 15.84% year-over-year, with the annual reading at $11.0 million for FY2025, 15.84% up from the prior year.
  • Inventory hit $11.0 million in Q4 2025 for Vanda Pharmaceuticals, up from $2.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $11.1 million in Q3 2022 to a low of $902000.0 in Q3 2021.
  • Historically, Inventory has averaged $5.2 million across 5 years, with a median of $1.8 million in 2024.
  • Biggest five-year swings in Inventory: skyrocketed 1125.83% in 2022 and later crashed 90.9% in 2023.
  • Year by year, Inventory stood at $1.0 million in 2021, then grew by 16.49% to $1.2 million in 2022, then increased by 13.65% to $1.4 million in 2023, then surged by 601.03% to $9.5 million in 2024, then increased by 15.84% to $11.0 million in 2025.
  • Business Quant data shows Inventory for VNDA at $11.0 million in Q4 2025, $2.0 million in Q3 2025, and $10.4 million in Q2 2025.